Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill (2016 - 2025)

Historic Goodwill for Ani Pharmaceuticals (ANIP) over the last 13 years, with Q3 2025 value amounting to $62.5 million.

  • Ani Pharmaceuticals' Goodwill rose 339.92% to $62.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.5 million, marking a year-over-year increase of 339.92%. This contributed to the annual value of $60.0 million for FY2024, which is 11257.22% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Goodwill of $62.5 million as of Q3 2025, which was up 339.92% from $60.5 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill peaked at $62.5 million during Q3 2025, and registered a low of $3.6 million during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Goodwill value was $28.2 million (recorded in 2022), while the average stood at $32.9 million.
  • Its Goodwill has fluctuated over the past 5 years, first changed by 0.0% in 2021, then soared by 68829.61% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill (Quarter) stood at $27.9 million in 2021, then grew by 1.15% to $28.2 million in 2022, then changed by 0.0% to $28.2 million in 2023, then soared by 112.57% to $60.0 million in 2024, then grew by 4.15% to $62.5 million in 2025.
  • Its Goodwill was $62.5 million in Q3 2025, compared to $60.5 million in Q2 2025 and $60.7 million in Q1 2025.